Nature Medicine, Published online: 12 May 2026; doi:10.1038/s41591-026-04399-2
The BIOMEDE trial, although negative for its primary endpoint, illustrates the utility of adaptive trial designs and biopsy-informed tumor profiling in guiding treatment decisions and patient counseling — and provides mechanistic evidence that can inform future therapeutic strategies.
